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In osteoarthritis (OA) the synovium is often inﬂamed and inﬂammatory cytokines contribute to cartilage
damage. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have anti-inﬂammatory effects whereas
omega-6 polyunsaturated fatty acids (n-6 PUFAs) have, on balance, proinﬂammatory effects. The goal of
our study was to assess the association of fasting plasma phospholipid n-6 and n-3 PUFAs with synovitis
as measured by synovial thickening on contrast enhanced (CE) knee MRI and cartilage damage among
subjects in the Multicenter Osteoarthritis Study (MOST).
MOST is a cohort study of individuals who have or are at high risk of knee OA. An unselected subset of
participants who volunteered obtained CE 1.5 T MRI of one knee. Synovitis was scored in six compart-
ments and a summary score was created. This subset also had fasting plasma, analyzed by gas chro-
matography for phospholipid fatty acid content, and non-CE MRI, read for cartilage morphology
according to the Whole-Organ Magnetic Resonance Imaging Score (WORMS) method. The association
between synovitis and cartilage morphology and plasma PUFAs was assessed using logistic regression
after controlling for the effects of age, sex, and BMI.
472 out of 535 subjects with CE MRI had complete data on synovitis, cartilage morphology and plasma
phospholipids. Mean age was 60 years, mean BMI 30, and 50% were women. We found an inverse
relation between total n-3 PUFAs and the speciﬁc n-3, docosahexaenoic acid with patellofemoral carti-
lage loss, but not tibiofemoral cartilage loss or synovitis. A positive association was observed between the
n-6 PUFA, arachidonic acid, and synovitis.
In conclusion, systemic levels of n-3 and n-6 PUFAs which are inﬂuenced by diet, may be related to
selected structural ﬁndings in knees with or at risk of OA. Future studies manipulating the systemic levels
of these fatty acids may be warranted to determine the effects on structural damage in knee OA.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is highly common in older adults and few
treatments are available none of which target structural abnor-
malities in the joint1,2. Aside from cartilage and bone, OA affectsristin Baker, College of Health
niversity, 635 Commonwealth
tates. Tel: 1-617-358-1637;
s Research Society International. Pligaments, muscles, and synovium. OA is thought to be an inﬂam-
matory disorder with low grade inﬂammation affecting the syno-
vium and inﬂammatory cytokines contributing to the cartilage
damage which is the signature pathologic feature of disease3. Ayral
et al. reported that synovitis tends to cause cartilage loss in the
region where the synovitis occurs4.
In previous work, we found a high prevalence of knee synovitis
as measured by synovial thickening in contrast enhanced (CE) knee
MRI in theMulticenter Osteoarthritis Study (MOST)5. Synovitis of at
least a mild degree was found in 56% of those with no radiographic
knee OA and 67% of those with radiographic knee OA.ublished by Elsevier Ltd. All rights reserved.
Table I
Characteristics of 472 subjects with CE knee MRI and plasma phospholipid
fatty acids
Age, mean SD 59.9 7.3 years
Women 50%
BMI, mean SD 29.5 4.8 kg/m2
Synovitis
None/questionable 33.3%
Mild 51.4%
Moderate 12.6%
Severe 2.7%
Whole knee radiographic OA 34%
K.R. Baker et al. / Osteoarthritis and Cartilage 20 (2012) 382e387 383Omega-6 and omega-3 polyunsaturated fatty acids (n-6 and n-3
PUFAs) are directly linked to inﬂammation via their role as
precursors for a family of compounds known as eicosanoids.
Eicosanoids are mediators and regulators of inﬂammation. Arach-
idonic acid (AA) is the primary n-6 PUFA found in inﬂammatory
cells and leads to the production of inﬂammatory eicosanoids.
Studies have shown increasing the amount of either AA or its
precursor linoleic acid (LA; 18:2n-6) in the diet increases the
content of AA in inﬂammatory cells and the production of inﬂam-
matory eicosanoids6. Higher levels of AA in the blood and/or dietary
intake have been tied to more platelet aggregation and increased
atherosclerosis in a subpopulation with a genetic variation in
5-lipoxygenase, an enzyme that generates inﬂammatory leukotri-
enes from AA7e9. In rheumatoid arthritis, a diet low in AA
ameliorates clinical signs of inﬂammation10.
The n-3 PUFA, eicosapentaenoic acid (EPA; 20:5n-3) and doco-
sahexaenoic acid (DHA; 22:6n-3) give rise to eicosanoids with
a slightly different structure from those formed from AA. The
functional signiﬁcance is that these eicosanoids are less potent
mediators of inﬂammation. Increased consumption of EPA and DHA
results in increased proportions of these fatty acids in inﬂammatory
cells and occurs in a dose response fashion and at the expense of
AA11,12. So in addition to forming less inﬂammatory eicosanoids,
less substrate is available for the formation of AA derived
eicosanoids.
In multiple trials treatment with n-3 PUFAs, predominantly EPA
and DHA, resulted in lower levels of proinﬂammatory markers and
higher levels of anti-inﬂammatory markers13,14 and better
outcomes in numerous diseases including RA15,16 and cardiovas-
cular disease17e19. Also, in cartilage cell cultures n-3 PUFAs have
been shown to inhibit the transcription of major enzymes and
cytokines tied to matrix degradation20.
The precursors to AA and (EPA and DHA), LA; 18:2n-6 and alpha
linolenic acid (ALA; 18:3n-3) respectively, are essential in the diet.
The predominant dietary n-6 PUFA is LA that is converted to AA, in
addition some AA is obtained by meat consumption. The predom-
inant dietary n-3 PUFA is ALA, and research shows that only a very
small portion is converted to the long chain n-3 EPA and DHA thatTable IIa
Association of AA with CE knee MRI synovitis (n¼ 472)
AA (mol%)
Synovitis 5.09.2 (n¼ 120) 9.310.4 (n¼ 11
Normal/questionable 47 (39%) 42 (35%)
Mild 59 (49%) 61 (52%)
Moderate/severe 14 (12%) 15 (13%)
Adj. OR for mild vs normal
synovitis (95% CI)
1.0 1.1 (0.7, 2.0)
Adj. OR for moderate/severe vs
normal synovitis (95% CI)
1.0 1.2 (0.5, 3.0)
Adjusted for age, sex and BMI.seem to be the more potent inhibitors of inﬂammation21. Sources of
EPA and DHA in the diet include fatty ﬁsh like salmon, tuna,
anchovies, sardines and shellﬁsh, shrimp and Alaskan king crab.
The current Western diet is higher in n-6 fatty acids with an n-6 to
n-3 ratio of 20e30 to 122. This ratio has increased dramatically over
the years with food processing, less ﬁsh consumption, and the
dietary habits of our farm animals.
The goal of our study was to assess the association of fasting
plasma phospholipid n-6 (AA) and n-3 PUFAs (EPA and DHA) with
synovitis as measured by synovial thickening on CE knee MRI
among subjects in MOST. Since cartilage loss on MRI may also
reﬂect the inﬂuence of local inﬂammation, which may, in turn, be
related to systemic inﬂammation, we also examined the relation of
cartilage loss with these n-6 and n-3 PUFA levels. Potential ﬁndings
could lead to dietary recommendations for fatty acid intake to
ameliorate inﬂammation related to OA.Methods
The MOST is the parent study for this investigation of knee pain
and synovitis and has been described elsewhere5. All subjects were
recruited from two US communities, Birmingham, Alabama and
Iowa City, Iowa. Subjects were excluded if they screened positive
for RA, had ankylosing spondylitis, psoriatic arthritis, chronic
reactive arthritis, had renal problems resulting in a need for hemo-
or peritoneal dialysis, a history of cancer (except for non-melanoma
skin cancer), bilateral knee replacement surgery, inability to walk
without the help of another person or walker, or were planning to
move out of the area in the next 3 years. Persons who had no
contraindications toMRI andwhowerewilling obtained extremity-
based MRI’s (see below) repeatedly throughout the study. The
protocol for MOST was approved by IRB’s at University of Iowa,
University of Alabama, Birmingham, University of California, San
Francisco and Boston University Medical Center.
For this investigation on synovitis, a subset of MOST subjects
with the following inclusion criteria were investigated: vol-
unteered to undergo a 1.5 T CE MRI of one knee at the 30 month
follow-up clinic visit. Radiographs had already been obtained and
read and we selected the knee with the lower Kellgren Lawrence
grade for CE MRI. If the grade was the same for both knees, the
dominant leg was chosen. Subjects with Kellgren and Lawrence
grade of 4 in both knees were ineligible. For those subjects with
kidney disease, diabetes or over the age of 65, a serum creatinine
was obtained and the glomerular ﬁltration rate calculated before
gadolinium injections. Those subjects with renal insufﬁciency were
excluded from this substudy.MRI measurements
CE MRIs were obtained at 30 months with a 1.5-T system
(Siemens Symphony) with a circumferential extremity coil.P for trend
8) 10.511.8 (n¼ 115) 11.917.7 (n¼ 119)
43 (37%) 38 (32%)
54 (47%) 54 (45%)
18 (16%) 27 (23%)
1.0 (0.6, 1.8) 1.1 (0.6, 2.0) 0.80
1.6 (0.7, 3.8) 2.8 (1.2, 6.4) 0.01
Table IIb
Association of AA with maximal TF and PF cartilage morphology
AA (mol%) P for trend
Tibiofemoral cartilage 5.09.2 (n¼ 120) 9.310.4 (n¼ 110) 10.511.8 (n¼ 103) 11.917.7 (n¼ 104)
0e1 23 (21%) 16 (15%) 13 (13%) 13 (13%)
2e3 52 (47%) 55 (50%) 55 (53%) 53 (51%)
4 36 (32%) 39 (36%) 35 (34%) 38 (37%)
Adj. OR for 2e3 vs 0 (95% CI) 1.0 1.5 (0.7, 3.1) 1.8 (0.8, 4.0) 1.7 (0.8, 3.8) 0.14
Adj. OR for 4þ vs 0 (95% CI) 1.0 1.5 (0.7, 3.4) 1.8 (0.8, 4.0) 1.8 (0.8, 4.1) 0.15
Patellofemoral cartilage (n¼ 110) (n¼ 110) (n¼ 102) (n¼ 102)
0e1 29 (26%) 26 (24%) 26 (26%) 25 (25%)
2e3 50 (46%) 49 (45%) 48 (47%) 46 (45%)
4 31 (28%) 35 (32%) 28 (28%) 31 (30%)
Adj. OR for 2e3 vs 0 (95% CI) 1.0 1.1 (0.6, 2.2) 1.1 (0.5, 2.1) 1.1 (0.5, 2.1) 0.92
Adj. OR for 4þ vs 0 (95% CI) 1.0 1.4 (0.7, 2.9) 1.2 (0.5, 2.5) 1.2 (0.6, 2.6) 0.76
Adjusted for age, sex and BMI.
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(TR¼ 600 ms, TE¼ 13 ms, 3.0 slice thickness, 0.3 mm interslice gap,
FOV 1616 cm, matrix 512512, ETL 1). Intravenous gadolinium
(Magnevist (gadopentetate dimeglumine) or Omniscan (gado-
diamide)) was administered at a dose of 0.2 ml (0.1 mmol)/kg body
weight. Two minutes after completing the injection of the gadoli-
nium, sagittal sequences were obtained immediately followed by
the axial sequences.
The MOST parent study MRIs were also performed at 30 months
on a 1.0 T extremity-based Orthone magnet (OrthOne, ONI Inc.,
Wilmington, MA) with a circumferential extremity coil for which
CE scans were not advisable. These MRI’s were acquired using fat
suppressed fast spin echo proton density weighted sequence in two
planes, sagittal (TR 4800, TE 35, slice thickness 3 mm, 0 mm
interslice gap, FOV 14 cm, 288192 matrix, NEX 2), and axial (TR
4700, TE 13.2, slice thickness 3 mm, 0 mm interslice gap, FOV
14 cm, 288192 matrix, NEX 2) and a STIR sequence in the coronal
plane (TR 7820, TE 14, TI 100, slice thickness 3 mm, 0 mm interslice
gap, FOV 14 cm, 256256 matrix, NEX 2).
MRI reading
For the MRI readings we equated synovial thickening with
synovitis. Using a protocol described elsewhere5, synovitis on CE
MRI using axial and sagittal T1-weighted sequences was scored
separately at six sites (medial and lateral parapatellar recesses,
suprapatellar pouch, infrapatellar fat pad, and medial and lateral
posterior condyles). Degree of synovitis was scored semi-
quantitatively (0e3) in the medial and lateral parapatellar recesses,
suprapatellar pouch and the infrapatellar fat pad. For the posterior
medial and lateral femoral condyles, we scored synovitis as either
present (1) or absent (0). This semiquantitative scoring method has
been validated in CE MRI23. One reader (KB), trained by a muscu-
loskeletal radiologist (AGr) and blinded to pain scores, read syno-
vitis on CE MRIs.
As previously reported5 to obtain a summary score for the six
regions where synovitis was scored on CE MRI, we created theTable IIIa
Association of total n-3 PUFAs with CE knee MRI synovitis (n¼ 472)
n-3 Fatty acids (mol%
Synovitis 2.1e3.2 (n¼ 122)
Normal/questionable 43 (36%)
Mild 60 (50%)
Moderate/severe 16 (14%)
Adj. OR for mild vs normal synovitis (95% CI) 1.0
Adj. OR for moderate/severe vs normal synovitis (95% CI) 1.0
Adjusted for age, sex and BMI.following categories; (1) normal or questionable; <4 sites scored as
1 and all other sites scored as 0, (2)mild;4 sites scored as 1 and/or
1 site scored as 2, (3) moderate; 2 sites scored as 2 and no score
of 3, (4) severe; 1 site scored as 3. Due to small numbers of MRI’s
classiﬁed as ‘moderate’ and ‘severe’ synovitis, these categories were
collapsed in the analysis.
To obtain information about other MRI features, we used the
non-CE MRI. Two musculoskeletal radiologists (AG and FR) read
non-CE MRIs for cartilage morphology according to the Whole-
Organ Magnetic Resonance Imaging Score (WORMS) method24. In
each of 10 subregions within the medial and lateral tibiofemoral
compartments and in four subregions of the PF compartment,
cartilage morphology was scored from 0 to 6 where 0 is normal
morphology and 6 is diffuse cartilage loss to bone. To classify the
amount of cartilage loss, we created three categories: normal
morphology (grades 0 and 1), erosions without more diffuse
cartilage loss (grades 2 and 3) and diffuse loss (4). To deﬁne the
amount of cartilage loss in a region (e.g., tibiofemoral compart-
ment), we took the maximal score of any subregion (e.g., central
medial femur) within that region.
Plasma phospholipid fatty acid analysis
Lipids were extracted from plasma25 drawn at the study base-
line after addition of an internal standard (25 mg of 1,2 diheptade-
canoyl-glycero-3-phosphocholine). The phospholipid subfraction
was separated by solid-phase extraction using aminopropyl
columns26, saponiﬁed and then methylated27. The supernatant
containing the fatty acid methyl esters (FAME’s) was dried down
under nitrogen, resuspended in 100 ul of hexane, transferred into
amber GC vials and stored at 20C until the time of analysis.
The phospholipid FAMEs were analyzed by an Autosystem XL
gas chromatograph (Perkin Elmer, Boston, MA) equipped with
a 30 m0.25 mm i.d. (ﬁlm thickness 0.25 mm) capillary column (HP
INNOWAX, Agilent Technologies, DE) as previously described18,28.
Peaks of interest were identiﬁed by comparison with authentic
fatty acid standards (Nu-Chek Prep, Inc., MN) and expressed as) P for trend
3.3e4.0 (n¼ 124) 4.1e4.7 (n¼ 116) 4.8e15.9 (n¼ 110)
53 (41%) 39 (33%) 35 (33%)
57 (44%) 60 (50%) 51 (49%)
19 (15%) 20 (17%) 19 (18%)
0.9 (0.5, 1.5) 1.4 (0.8, 2.4) 1.1 (0.6, 2.0) 0.43
1.1 (0.5, 2.4) 1.2 (0.5, 2.9) 1.3 (0.6, 3.1) 0.44
Table IIIb
Association of total n-3 PUFAs with maximal TF and PF cartilage damage based on worst WORMS score (n¼ 472)
n-3 Fatty acids (mol%) P for trend
Tibiofemoral cartilage 2.1e3.2 (n¼ 117) 3.3e4.0 (n¼ 104) 4.1e4.7 (n¼ 104) 4.8e15.9 (n¼ 103)
0e1 21 (18%) 16 (15%) 13 (13%) 15 (15%)
2e3 54 (46%) 53 (51%) 49 (47%) 59 (57%)
4 42 (36%) 35 (34%) 42 (40%) 29 (28%)
Adj. OR for 2e3 vs 0 (95% CI) 1.0 1.3 (0.6, 2.8) 1.5 (0.7, 3.4) 1.6 (0.8, 3.5) 0.23
Adj. OR for 4þ vs 0 (95% CI) 1.0 1.1 (0.5, 2.5) 1.6 (0.7, 3.7) 0.9 (0.4, 2.1) 0.93
Patellofemoral cartilage (n¼ 117) (n¼ 102) (n¼ 103) (n¼ 102)
0e1 31 (27%) 21 (21%) 24 (23%) 30 (29%)
2e3 47 (40%) 49 (48%) 54 (48%) 54 (47%)
4 39 (33%) 32 (31%) 30 (29%) 24 (24%)
Adj. OR for 2e3 vs 0 (95% CI) 1.0 1.5 (0.7, 2.9) 1.3 (0.7, 2.5) 1.0 (0.5, 1.9) 0.74
Adj. OR for 4þ vs 0 (95% CI) 1.0 1.2 (0.6, 2.5) 0.9 (0.4, 2.0) 0.5 (0.2, 1.1) 0.05
Adjusted for age, sex and BMI.
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internal standard. Pooled plasma samples used as additional
controls were run weekly. On average the coefﬁcient of variations
ranges from 0.5% to 4.3% for fatty acids present at levels > mol%,
1.8e7.1% for fatty acids present at levels between 1 mol% and5 mol
%, and 2.8e11.1% for fatty acids present at levels <1 mol%.
Analysis
We evaluated the cross-sectional association between synovitis
and cartilage morphology and plasma phospholipid fatty acids (AA,
EPA, DHA, and total n-6 and n-3 PUFAs) using logistic regression.
We controlled for the effects of age, sex, BMI on synovitis. In these
analyses, the MRI feature was treated as a dichotomous dependent
variable and fatty acid category was the independent variable.
When therewere three levels of theMRI feature (e.g., synovitis), we
carried out two separate logistic regressions, each using normal/
questionable as one of the dichotomous categories. We also per-
formed proportional logistic regression (which uses all the data in
one analysis but did not allow us to use the non-synovitis or normal
cartilage group as the sole referent as a dependent variable) and
came up with similar ﬁndings. All analyses were performed using
SAS 9.1 (SAS Institute, Cary, NC). Due to possible confounding by
indicationwe initially excluded those taking fatty acid supplements
(n¼ 17). However, results were the same when these 17 persons
were left in the analysis. Results presented include the 17 taking
supplements.
Results
The sample studied consisted of equal numbers of men and
women (see Table I) with a mean age of 60 years. Approximately
one-third showed evidence of X-ray OA in the studied knee and
about 2/3’s had signs of synovitis on MRI.
We examined total n-6 PUFAs and found no association with
either synovitis or cartilage loss (data not shown). But when we
examined AA levels, we found that higher levels of this n-6 PUFATable IVa
Association of DHA with CE knee MRI synovitis (n¼ 472)
DHA (mol%)
Synovitis 1.1e1.92 (n¼ 123)
Normal/questionable 53 (43%)
Mild 53 (43%)
Moderate/severe 17 (14%)
Adj. OR for mild vs normal synovitis (95% CI) 1.0
Adj. OR for moderate/severe vs normal synovitis (95% CI) 1.0
Adjusted for age, sex and BMI.were associated with more synovitis (Table IIa) although not with
cartilage loss (Table IIb).
We next examined total n-3 PUFAs and their relation to struc-
tural ﬁndings in the knee and found that there was no association
with synovitis (Table IIIa), but higher levels of total n-3 PUFAs were
associated with less severity of patellofemoral (Table IIIb), but not
tibiofemoral cartilage loss. Similarly, for DHA we found no associ-
ationwith synovitis (Table IVa) but did ﬁnd a relation of higher DHA
levels with less patellofemoral cartilage loss (Table IVb) although
not with tibiofemoral loss. For EPA levels, another n-3, we found no
association with either synovitis or cartilage loss in any compart-
ment (data not shown). Results were similar whether the PUFAs
were analyzed in quartiles or tertiles.
Discussion
Our results, examining fasting plasma levels of n-6 and n-3
PUFAs and OA, suggest subjects in MOST with high levels of total
n-3 PUFAs (in the fourth quartile), speciﬁcally DHA, had lower
patellofemoral cartilage loss. In contrast, MOST subjects with
higher levels of AA tended to have higher synovitis severity.
We are unaware of other studies that have looked in vivo at the
relation of n-6 and n-3 PUFA levels with knee structures in OA.
There have been studies on the association of fatty acids with OA in
general or elements related to disease. For example, in a study
looking at fat in OA bone, levels of n-6 PUFAs, especially AA was
almost double that seen in a comparator osteoporotic bone29. Also,
in patients undergoing joint replacement surgery for OA, those
taking ﬁsh oils (rich in n-3 PUFAs) before surgery had a near
doubling of long chain fatty acids in synovial ﬂuid and bone
marrow compared to before supplementation30. AA has been
shown to be increased in cartilage, serum, and synovial ﬂuid in OA
patients compared to non-OA31.
We found an effect of both total n-3 PUFAs and of DHA on
patellofemoral cartilage loss. These two analytes are not synony-
mous,withDHA representingonlya small fractionof total n-3 PUFAs
but representing one of the biologically active fractions. Our resultsP for trend
2.0e2.4 (n¼ 118) 2.5e3.0 (n¼ 120) 3.1e7.7 (n¼ 111)
36 (31%) 40 (33%) 41 (37%)
66 (56%) 55 (46%) 54 (49%)
16 (14%) 25 (21%) 16 (14%)
1.9 (1.1, 3.3) 1.4 (0.8, 2.4) 1.4 (0.8, 2.4) 0.52
1.4 (0.6, 3.3) 1.6 (0.8, 3.6) 1.1 (0.5, 2.5) 0.86
Table IVb
Association of DHA with maximal TF and PF cartilage morphology (n¼ 472)
DHA (mol%) P for trend
Tibiofemoral cartilage 1.1e1.9 (n¼ 113) 2.0e2.4 (n¼ 103) 2.5e3.0 (n¼ 108) 3.1e7.7 (n¼ 104)
0e1 19 (17%) 16 (16%) 15 (14%) 15 (14%)
2e3 57 (50%) 47 (46%) 51 (47%) 60 (58%)
4 37 (33%) 40 (39%) 42 (39%) 29 (28%)
Adj. OR for 2e3 vs 0 (95% CI) 1.0 1.0 (0.5, 2.2) 1.1 (0.5, 2.5) 1.4 (0.7, 3.2) 0.33
Adj. OR for 4þ vs 0 (95% CI) 1.0 1.2 (0.5, 2.7) 1.3 (0.6, 3.0) 0.9 (0.4, 2.1) 0.85
Patellofemoral cartilage (n¼ 113) (n¼ 101) (n¼ 117) (n¼ 103)
0e1 29 (26%) 20 (20%) 26 (24%) 31 (30%)
2e3 47 (42%) 49 (49%) 50 (47%) 47 (46%)
4 37 (33%) 32 (32%) 31 (29%) 25 (25%)
Adj. OR for 2e3 vs 0 (95% CI) 1.0 1.4 (0.6, 2.9) 1.1 (0.6, 2.1) 0.9 (0.4, 1.7) 0.46
Adj. OR for 4þ vs 0 (95% CI) 1.0 1.0 (0.5, 2.2) 0.8 (0.4, 1.6) 0.5 (0.2, 1.0) 0.04
Adjusted for age, sex and BMI.
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disease have also reported an association uniquely with DHA32.
Why would there be an effect of relevant fatty acids on patello-
femoral but not tibiofemoral cartilage?We are not sure but note that
Ayral et al.4 in a longitudinal arthroscopy study reported that carti-
lage loss occurred only adjacent to active synovitis and not distant
from it. Synovitis predominates in the parapatellar area33. In our
study subset, all subjects with moderate to severe synovitis had this
inﬂammation in the parapatellar region. Therefore, it is possible that
the patellar cartilage loss we saw was due to this adjacent synovitis
and that synovitis did not invest the tibiofemoral compartment.
We acknowledge that our ﬁndings are not consistent across n-6
and n-3 PUFAs or their components and some of our results are
null. The inconsistent and null ﬁndings may partially be explained
by the observational nature of the study. The levels of n-3 PUFAs did
not attain levels reached in clinical trials where subjects are sup-
plemented with n-3 PUFAs. As mentioned earlier, the Western diet
is much higher in n-6 than n-3 PUFAs thereby reducing the
potential anti-inﬂammatory beneﬁts of n-3 PUFAs. In some trials
the intake of n-6 PUFAs was restricted in conjunction with n-3
supplementation, and in these trials an enhanced beneﬁt for n-3
PUFAs was seen34,35.
We interpret our ﬁndings as indicating a potential positive effect
on synovitis and cartilage loss of n-3 PUFAs and negative effect of n-
6 PUFAs, speciﬁcally AA. As the ﬁrst descriptive observational study
of these fatty acids and their relation to relevant structural abnor-
malities, we hope that these results generate further investigations
that may clarify our ﬁndings.
There are several limitations when interpreting our data. We
were only able to obtain one measurement of fatty acid intake at
baseline. The measurement will be affected by current fatty acid
intake and there is the potential for misclassiﬁcation. We cannot
make causal inferences because we have not manipulated the diet
and we do not have longitudinal data. And, an observational
association of health behaviors, such as dietary fatty acid intake,
with disease may only indicate an indirect connection (i.e., those
with a healthy diet also exhibit other behaviors that are beneﬁcial
to their joints).
In conclusion, this observational study suggests that future
studies manipulating the systemic levels of n-6 and n-3 PUFAs,
which are inﬂuenced by diet, may be warranted to determine the
effects of these fatty acids on synovitis and cartilage loss in knees
with or at risk of OA.
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